

NCT Number	Study Title	Study URL	Study Status	Conditions
NCT05912621	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	https://clinicaltrials.gov/study/NCT05912621	RECRUITING	Obesity Overweight and Obesity Overweight
NCT03375463	A Study of Tirzepatide (LY3298176) in Healthy Participants	https://clinicaltrials.gov/study/NCT03375463	COMPLETED	Healthy
NCT06635057	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan	https://clinicaltrials.gov/study/NCT06635057	ACTIVE_NOT_RECRUITING	Type 2 Diabetes
NCT05978713	A Study of Tirzepatide (LY3298176) in Healthy Lactating Females	https://clinicaltrials.gov/study/NCT05978713	COMPLETED	Healthy
NCT06864026	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	https://clinicaltrials.gov/study/NCT06864026	RECRUITING	Psoriatic Arthritis Overweight or Obesity
NCT06857942	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	https://clinicaltrials.gov/study/NCT06857942	RECRUITING	Psoriasis Overweight or Obesity
NCT04050670	A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes	https://clinicaltrials.gov/study/NCT04050670	COMPLETED	Healthy
NCT05706506	A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	https://clinicaltrials.gov/study/NCT05706506	COMPLETED	Type 2 Diabetes Diabetes Mellitus, Type 2
NCT05708859	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	https://clinicaltrials.gov/study/NCT05708859	RECRUITING	Type II Diabetes Atherosclerosis
NCT06191848		https://clinicaltrials.gov/study/NCT06191848	RECRUITING	Obesity Knee Osteoarthritis Osteoarthritis, Knee
NCT03482024	A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function	https://clinicaltrials.gov/study/NCT03482024	COMPLETED	Renal Insufficiency End Stage Renal Disease
NCT03940742	A Study of Tirzepatide in Participants With Impaired Liver Function	https://clinicaltrials.gov/study/NCT03940742	COMPLETED	Hepatic Insufficiency
NCT06890611	A Study of Bimagrimumab Alone (LY3985863) and Bimagrimumab With Tirzepatide (LY900042) in Healthy Participants	https://clinicaltrials.gov/study/NCT06890611	ACTIVE_NOT_RECRUITING	Healthy
NCT06037252	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	https://clinicaltrials.gov/study/NCT06037252	ACTIVE_NOT_RECRUITING	Type 2 Diabetes Obesity
NCT06914895	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	https://clinicaltrials.gov/study/NCT06914895	RECRUITING	Type 1 Diabetes Obesity Overweight
NCT06662383	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity	https://clinicaltrials.gov/study/NCT06662383	ACTIVE_NOT_RECRUITING	Obesity
NCT06962280	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	https://clinicaltrials.gov/study/NCT06962280	RECRUITING	Type 1 Diabetes Obesity Overweight
NCT06439277	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	https://clinicaltrials.gov/study/NCT06439277	RECRUITING	Obesity Weight Gain
NCT05963022	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)	https://clinicaltrials.gov/study/NCT05963022	COMPLETED	Type 2 Diabetes
NCT06588296	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight	https://clinicaltrials.gov/study/NCT06588296	ACTIVE_NOT_RECRUITING	Psoriatic Arthritis Obesity
NCT05696847	A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity	https://clinicaltrials.gov/study/NCT05696847	COMPLETED	Obesity
NCT06588283	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight	https://clinicaltrials.gov/study/NCT06588283	ACTIVE_NOT_RECRUITING	Psoriasis Obesity
NCT06901349	A Study of Bimagrimumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT06901349	ACTIVE_NOT_RECRUITING	Obesity Overweight
NCT06075667	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	https://clinicaltrials.gov/study/NCT06075667	ACTIVE_NOT_RECRUITING	Obesity Overweight
NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT05691712	COMPLETED	Diabetes Type 2 Diabetes Mellitus Glucose Metabolism
NCT05556512	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	https://clinicaltrials.gov/study/NCT05556512	ACTIVE_NOT_RECRUITING	Obesity Overweight
NCT04407234	A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide	https://clinicaltrials.gov/study/NCT04407234	COMPLETED	Overweight Obesity Diabetes Mellitus, Type 2

NCT Number	Interventions	Sponsor	Collaborators	Study Type
NCT05912621	DRUG: Tirzepatide	Stanford University	Eli Lilly and Company	INTERVENTIONAL
NCT03375463	DRUG: Tirzepatide DRUG: Tirzepatide DRUG: Placebo DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT06635057	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT05978713	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT06864026	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT06857942	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT04050670	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT05706506	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT05708859	DRUG: Tirzepatide DRUG: Placebo	Matthew J. Budoff	Eli Lilly and Company	INTERVENTIONAL
NCT06191848	DRUG: Tirzepatide DRUG: Placebo	University of Melbourne	Eli Lilly and Company	INTERVENTIONAL
NCT03482024	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT03940742	DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT06890611	DRUG: Bimagrumab DRUG: Tirzepatide DRUG: Bimagrumab + Tirzepatide Coformulation	Eli Lilly and Company		INTERVENTIONAL
NCT06037252	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06914895	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06662383	DRUG: Retatrutide DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT06962280	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06439277	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05963022	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06588296	DRUG: Ixekizumab DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT05696847	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06588283	DRUG: Ixekizumab DRUG: Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT06901349	DRUG: Bimagrumab DRUG: Tirzepatide DRUG: Bimagrumab Placebo DRUG: Tirzepatide Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06075667	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05691712	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05556512	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04407234	DRUG: Tirzepatide DRUG: Acetaminophen	Eli Lilly and Company		INTERVENTIONAL

NCT Number	Study Title	Study URL	Study Status	Conditions
	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities			
NCT06047548	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	https://clinicaltrials.gov/study/NCT06047548	ACTIVE_NOT_RECRUITING	Overweight Obesity
NCT05822830	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	https://clinicaltrials.gov/study/NCT05822830	COMPLETED	Obesity Overweight
NCT06643728	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	https://clinicaltrials.gov/study/NCT06643728	RECRUITING	Obesity Overweight
NCT05536804	Study of Tirzepatide in Healthy Participants	https://clinicaltrials.gov/study/NCT05536804	ACTIVE_NOT_RECRUITING	Overweight Obesity Chronic Kidney Disease Type 2 Diabetes
NCT04311424	Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea	https://clinicaltrials.gov/study/NCT04311424	COMPLETED	Healthy
NCT05412004	A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease	https://clinicaltrials.gov/study/NCT05412004	COMPLETED	Obstructive Sleep Apnea Obesity
NCT04844918	A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity	https://clinicaltrials.gov/study/NCT04844918	COMPLETED	Obesity
NCT06373146		https://clinicaltrials.gov/study/NCT06373146	ACTIVE_NOT_RECRUITING	Obesity
NCT06297616	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	https://clinicaltrials.gov/study/NCT06297616	ACTIVE_NOT_RECRUITING	Obesity Overweight
NCT04847557	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	https://clinicaltrials.gov/study/NCT04847557	COMPLETED	Obesity Heart Failure With Preserved Ejection Fraction (
NCT04657003	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	https://clinicaltrials.gov/study/NCT04657003	COMPLETED	Type 2 Diabetes Overweight Obesity
NCT05024032	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	https://clinicaltrials.gov/study/NCT05024032	COMPLETED	Obesity Overweight Metabolism and Nutrition Disorder
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT04255433	COMPLETED	Type 2 Diabetes Mellitus
NCT04166773	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	https://clinicaltrials.gov/study/NCT04166773	COMPLETED	Nonalcoholic Steatohepatitis
NCT04660643	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss	https://clinicaltrials.gov/study/NCT04660643	COMPLETED	Obesity Overweight
NCT06354101	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	https://clinicaltrials.gov/study/NCT06354101	WITHDRAWN	Metabolic Health
NCT05564039	A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)	https://clinicaltrials.gov/study/NCT05564039	COMPLETED	Type 2 Diabetes
NCT04657016	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program	https://clinicaltrials.gov/study/NCT04657016	COMPLETED	Obesity Overweight
NCT04039503	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	https://clinicaltrials.gov/study/NCT04039503	COMPLETED	Type 2 Diabetes
NCT03954834	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone	https://clinicaltrials.gov/study/NCT03954834	COMPLETED	Type 2 Diabetes Mellitus
NCT03861052	A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT03861052	COMPLETED	Type 2 Diabetes
NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	https://clinicaltrials.gov/study/NCT04184622	COMPLETED	Overweight Obesity
NCT04081337	A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide	https://clinicaltrials.gov/study/NCT04081337	COMPLETED	Obesity
NCT04050553	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus	https://clinicaltrials.gov/study/NCT04050553	COMPLETED	Diabetes Mellitus, Type 2 Hypoglycemia
NCT03987919	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT03987919	COMPLETED	Type 2 Diabetes
NCT04235959	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	https://clinicaltrials.gov/study/NCT04235959	COMPLETED	Diabetes Mellitus, Type 2
NCT03311724	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT03311724	COMPLETED	Type 2 Diabetes

NCT Number	Interventions	Sponsor	Collaborators	Study Type
NCT06047548	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05822830	DRUG: Tirzepatide DRUG: Semaglutide	Eli Lilly and Company		INTERVENTIONAL
NCT06643728	DRUG: Bimagrumbab DRUG: Tirzepatide DRUG: Bimagrumbab Placebo DRUG: Tirzepatide Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05536804	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04311424	DRUG: 14C Tirzepatide	Eli Lilly and Company		INTERVENTIONAL
NCT05412004	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04844918	DRUG: Tirzepatide OTHER: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06373146	DRUG: Tirzepatide DRUG: Mibavademab DRUG: Tirzepatide-Placebo DRUG: Mibavademab-Placebo	Eli Lilly and Company	Regeneron Pharmaceuticals	INTERVENTIONAL
NCT06297616	DRUG: LY3841136 DRUG: LY3841136-Placebo DRUG: Tirzepatide DRUG: Tirzepatide-Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04847557	DRUG: Tirzepatide OTHER: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04657003	DRUG: Tirzepatide OTHER: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05024032	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04255433	DRUG: Tirzepatide DRUG: Dulaglutide	Eli Lilly and Company		INTERVENTIONAL
NCT04166773	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04660643	DRUG: Tirzepatide OTHER: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06354101	DRUG: Tirzepatide DRUG: Semaglutide	CorEvitas	Eli Lilly and Company	OBSERVATIONAL
NCT05564039	DRUG: Tirzepatide DRUG: Dulaglutide	Eli Lilly and Company		INTERVENTIONAL
NCT04657016	DRUG: Tirzepatide OTHER: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04039503	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT03954834	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT03861052	DRUG: Tirzepatide DRUG: Dulaglutide	Eli Lilly and Company		INTERVENTIONAL
NCT04184622	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04081337	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04050553	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT03987919	DRUG: Tirzepatide DRUG: Semaglutide	Eli Lilly and Company		INTERVENTIONAL
NCT04235959	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT03311724	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL

NCT Number	Study Title	Study URL	Study Status	Conditions
NCT03322631	A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT03322631	COMPLETED	Type 2 Diabetes Mellitus
NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	https://clinicaltrials.gov/study/NCT05260021	COMPLETED	Type2 Diabetes Diabetes Mellitus Diabetes Mellitus, Ty
NCT06603571	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT06603571	RECRUITING	Obesity Overweight
NCT06345066	A Study of LY3841136 in Overweight and Obese Participants	https://clinicaltrials.gov/study/NCT06345066	ACTIVE_NOT_RECRUITING	Obesity Overweight
NCT06515418	Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over	https://clinicaltrials.gov/study/NCT06515418	TERMINATED	Obesity
NCT05582096	A Study of LY3457263 in Obese Participants	https://clinicaltrials.gov/study/NCT05582096	COMPLETED	Overweight Obesity
NCT05433584	A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT05433584	ACTIVE_NOT_RECRUITING	Type 2 Diabetes
NCT04311411	A Study of Tirzepatide in Overweight and Very Overweight Participants	https://clinicaltrials.gov/study/NCT04311411	COMPLETED	Obesity Overweight
NCT04093752	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	https://clinicaltrials.gov/study/NCT04093752	COMPLETED	Type 2 Diabetes
NCT03951753	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	https://clinicaltrials.gov/study/NCT03951753	COMPLETED	Diabetes Mellitus, Type 2
NCT04172987	A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants	https://clinicaltrials.gov/study/NCT04172987	COMPLETED	Healthy
NCT03882970	A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT03882970	COMPLETED	Type 2 Diabetes Mellitus
NCT06937099	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	https://clinicaltrials.gov/study/NCT06937099	RECRUITING	Crohn's Disease Obesity or Overweight
NCT06916065	A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	https://clinicaltrials.gov/study/NCT06916065	RECRUITING	Overweight Obesity
NCT06937086	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study	https://clinicaltrials.gov/study/NCT06937086	RECRUITING	Ulcerative Colitis Obesity or Overweight
NCT03131687	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus	https://clinicaltrials.gov/study/NCT03131687	COMPLETED	Type 2 Diabetes Mellitus
NCT03730662	A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk	https://clinicaltrials.gov/study/NCT03730662	COMPLETED	Type 2 Diabetes Mellitus
NCT02759107	A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)	https://clinicaltrials.gov/study/NCT02759107	COMPLETED	Healthy Type 2 Diabetes Mellitus (T2DM)
NCT04537923	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	https://clinicaltrials.gov/study/NCT04537923	COMPLETED	Type 2 Diabetes
NCT03861039	A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	https://clinicaltrials.gov/study/NCT03861039	COMPLETED	Type 2 Diabetes Mellitus
NCT06143956	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	https://clinicaltrials.gov/study/NCT06143956	RECRUITING	Obesity Overweight
NCT04004988	A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants	https://clinicaltrials.gov/study/NCT04004988	COMPLETED	Healthy
NCT05810597	A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices	https://clinicaltrials.gov/study/NCT05810597	COMPLETED	Healthy
NCT06847399	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder	https://clinicaltrials.gov/study/NCT06847399	NOT_YET_RECRUITING	Obesity and Overweight Binge Eating Disorder
NCT06897475	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	https://clinicaltrials.gov/study/NCT06897475	RECRUITING	Type 2 Diabetes

NCT Number	Interventions	Sponsor	Collaborators	Study Type
NCT03322631	DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05260021	DRUG: Tirzepatide Dose 1 DRUG: Tirzepatide Dose 2 DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06603571	DRUG: LY3841136 DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06345066	DRUG: Tirzepatide DRUG: LY3841136 DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06515418	DRUG: Oral Azelaprag (BGE-105) DRUG: Oral Placebo for Azelaprag (BGE-105) DRUG: Tirzepatide DRUG: Tirzepatide Placebo	BioAge Labs, Inc.	Eli Lilly and Company	INTERVENTIONAL
NCT05582096	DRUG: LY3457263 DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT05433584	DRUG: Tirzepatide DRUG: Antihyperglycemic medication	Eli Lilly and Company		INTERVENTIONAL
NCT04311411	DRUG: Tirzepatide DRUG: Placebo DRUG: Liraglutide	Eli Lilly and Company		INTERVENTIONAL
NCT04093752	DRUG: Tirzepatide DRUG: Insulin Glargine	Eli Lilly and Company		INTERVENTIONAL
NCT03951753	DRUG: Tirzepatide DRUG: Semaglutide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT04172987	DRUG: Tirzepatide DRUG: EE/NGM	Eli Lilly and Company		INTERVENTIONAL
NCT03882970	DRUG: Tirzepatide DRUG: Insulin Degludec	Eli Lilly and Company		INTERVENTIONAL
NCT06937099	DRUG: Mirikizumab DRUG: Mirikizumab DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT06916065	DRUG: Eloralintide and Tirzepatide DRUG: Eloralintide	Eli Lilly and Company		INTERVENTIONAL
NCT06937086	DRUG: Mirikizumab DRUG: Mirikizumab DRUG: Tirzepatide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT03131687	DRUG: tirzepatide DRUG: Dulaglutide DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL
NCT03730662	DRUG: Tirzepatide DRUG: Insulin Glargine	Eli Lilly and Company		INTERVENTIONAL
NCT02759107	DRUG: Tirzepatide DRUG: Placebo DRUG: Dulaglutide	Eli Lilly and Company		INTERVENTIONAL
NCT04537923	DRUG: Tirzepatide DRUG: Insulin Lispro (U100)	Eli Lilly and Company		INTERVENTIONAL
NCT03861039	DRUG: Tirzepatide DRUG: Oral antihyperglycemic medication (OAM)	Eli Lilly and Company		INTERVENTIONAL
NCT06143956	DRUG: LY3305677 DRUG: LY3841136 DRUG: Tirzepatide DRUG: Placebo DRUG: LY3549492	Eli Lilly and Company		INTERVENTIONAL
NCT04004988	DRUG: Tirzepatide DEVICE: Prefilled syringe (PFS) DEVICE: Auto-injector (AI)	Eli Lilly and Company		INTERVENTIONAL
NCT05810597	DRUG: Tirzepatide DEVICE: Single Dose Pen DEVICE: Multi-use Prefilled Pen	Eli Lilly and Company		INTERVENTIONAL
NCT06847399	DRUG: Tirzepatide DRUG: Lisdexamfetamine Dimesylate BEHAVIORAL: Guided self-help cognitive behavioral therapy DRUG: Placebo (oral) DRUG: Placebo (injection)	Johns Hopkins University	Eli Lilly and Company	INTERVENTIONAL
NCT06897475	DRUG: LY3457263 DRUG: Placebo	Eli Lilly and Company		INTERVENTIONAL

NCT Number	Study Title	Study URL	Study Status	Conditions
NCT06009653	Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity	https://clinicaltrials.gov/study/NCT06009653	WITHDRAWN	Obesity Metabolic Disease

NCT Number	Interventions	Sponsor	Collaborators	Study Type
NCT06009653	BEHAVIORAL: Standard Care BEHAVIORAL: Culturally-tailored dietary and behavioral intensive lifestyle intervention DRUG: Placebo DRUG: Tirzepatide	Washington University School of Medicine	Eli Lilly and Company National Institute on Minority Health and Health Disparities (NIMHD)	INTERVENTIONAL